Recent research performed by the Imperial College London on the effects of "magic mushrooms" suggests psychedelic drugs may not be detrimental to our health. Psilocybin, a hallucinogenic chemical found in psychedelic mushrooms, is being tested as an alternative therapeutic treatment for depression and migraines.
The research found psilocybin reduces the overall amount of brain activity, which undermines previous scientific studies. Psilocybin temporarily severs connections in our brains, increasing our sensory awareness by allowing us to focus more intently on our environment.This is paradoxically characterized by decreased brain activity, causing hallucinations and bizarre sensations. Diseases such as depression, which can result from overactive involvement in certain portions of the brain, can potentially be treated by reducing brain activity. Psilocybin also reduces blood flow to the hypothalamus, decreasing the likelihood of severe headaches in patients with frequent migraines.
Researchers are currently studying the therapeutic applications of psilocybin.
Compiled by Kory Kianpour
Read More
U.Va. Health sees a spike in COVID-19 cases
By Emily Horn | September 4, 2023U.Va. Health ended their vaccination requirements in August, and masks were made optional in most hospital areas in early April.
U.Va. Cancer Center harnesses $12 million grant to support opportunities for undergraduates, ongoing research and new center
By Ellen Wu | January 12, 2023The grant provides an opportunity to establish the Center for Systems Analysis of Stress-Adapted Cancer Organelles, which seeks to find the cause of cancer in individual organelles.
U.Va. Health's rural neurology clinics receive a $500,000 grant to fund research and patient care
By Shrinidhi Kittur | January 12, 2023Established in the rural towns of Tazewell, Abingdon and Wise, the clinics have been providing patient care to otherwise underserved populations for decades.
